Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis

NCT06058299 is registered in ClinicalTrials.gov with Global Alliance for TB Drug Development as lead sponsor.

NCT NCT06058299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06058299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Partially-blinded, Randomised Trial Assessing the Safety and Efficacy of TBAJ-876 or Bedaquiline, in Combination With Pretomanid and Linezolid in Adult Participants With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis
Lead sponsor
Global Alliance for TB Drug Development
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2023
Completion date
February 28, 2027
Enrollment
309 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

drug sensitive tuberculosis, pulmonary tb, pulmonary tuberculosis